PT  - JOURNAL ARTICLE
AU  - Subhas Kumar Ghosh
AU  - Sachchit Ghosh
TI  - COVID-19: Risks of Re-emergence, Re-infection, and Control Measures – A Long Term Modeling Study
AID  - 10.1101/2020.09.19.20198051
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.09.19.20198051
4099  - http://medrxiv.org/content/early/2020/09/22/2020.09.19.20198051.short
4100  - http://medrxiv.org/content/early/2020/09/22/2020.09.19.20198051.full
AB  - In this work we define a modified SEIR model that accounts for the spread of infection during the latent period, infections from asymptomatic or pauci-symptomatic infected individuals, potential loss of acquired immunity, people’s increasing awareness of social distancing and the use of vaccination as well as non-pharmaceutical interventions like social confinement. We estimate model parameters in three different scenarios - in Italy, where there is a growing number of cases and re-emergence of the epidemic, in India, where there are significant number of cases post confinement period and in Victoria, Australia where a re-emergence has been controlled with severe social confinement program. Our result shows the benefit of long term confinement of 50% or above population and extensive testing. With respect to loss of acquired immunity, our model suggests higher impact for Italy. We also show that a reasonably effective vaccine with mass vaccination program can be successful in significantly controlling the size of infected population. We show that for India, a reduction in contact rate by 50% compared to a reduction of 10% in the current stage can reduce death from 0.0268% to 0.0141% of population. Similarly, for Italy we show that reducing contact rate by half can reduce a potential peak infection of 15% population to less than 1.5% of population, and potential deaths from 0.48% to 0.04%. With respect to vaccination, we show that even a 75% efficient vaccine administered to 50% population can reduce the peak number of infected population by nearly 50% in Italy. Similarly, for India, a 0.056% of population would die without vaccination, while 93.75% efficient vaccine given to 30% population would bring this down to 0.036% of population, and 93.75% efficient vaccine given to 70% population would bring this down to 0.034%.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe author(s) received no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:no IRBAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll of the data are publicly available and has been extracted from https://github.com/pcm-dpc/COVID-19, from https://github.com/CSSEGISandData/COVID-19, and from Covid19data.com.au https://github.com/pcm-dpc/COVID-19 https://github.com/CSSEGISandData/COVID-19 https://www.covid19data.com.au/